United States Patent 7,214,692: Scope, Claims, Expiration, and NK1 Antiemetic Patent Landscape

US Patent 7,214,692 covers the use of an NK1 receptor antagonist with a 5HT3 antagonist or systemic corticosteroid to treat or prevent emesis. Its most commercially relevant subject matter is the combination of an NK1 antagonist, such as aprepitant or a related compound, with ondansetron or granisetron for chemotherapy-induced nausea and vomiting.

The patent is no longer a current blocking right in the United States. Its claims had commercial significance for the Emend-aprepitant franchise and the broader NK1 antiemetic class, but generic and competing-product exposure is now governed primarily by other patents, regulatory exclusivity, product labeling, and formulation or manufacturing rights.

What does US Patent 7,214,692 protect?

The patent protects three principal categories:

Methods using an NK1 antagonist with a systemic corticosteroid or 5HT3 antagonist.
Pharmaceutical compositions containing both an NK1 antagonist and a 5HT3 antagonist.
Treatment regimens using the two agents separately but in a coordinated antiemetic regimen.

The central inventive concept is combination antiemetic therapy. The claims do not generally cover an NK1 antagonist alone, a 5HT3 antagonist alone, or the individual compounds as chemical entities.

Claim group	Subject matter	Commercial significance
Claims 1-9	NK1 antagonist combined with corticosteroid or 5HT3 antagonist	Broad combination-treatment coverage
Claim 10	NK1 antagonist chemical genus and pharmaceutically acceptable salts	Defines eligible NK1 antagonist structures
Claims 11-13	Composition containing NK1 antagonist and 5HT3 antagonist	Covers co-formulated products
Claims 14-21	Treatment or prevention of emesis using the combination	Covers clinical use
Claims 22-24	Dose limitations, including 3 mg/kg and 5 mg/kg	Narrows method protection
Claim 25	Separate administration according to an effective dosing regimen	Addresses sequential or separately administered therapy

How broad are claims 1 through 9?

Claim 1 is the principal broad method claim. It requires:

A mammal suffering from or susceptible to emesis;
Administration of an effective amount of an NK1 antagonist; and
Administration in combination with either:
- A systemic anti-inflammatory corticosteroid; or
- A 5HT3 antagonist.

Claim 1 is not limited to cancer chemotherapy. Claim 4 lists multiple causes of emesis, including radiation, pregnancy, vestibular disorders, surgery, gastrointestinal obstruction, migraine, altered intracranial pressure, and opioid analgesics.

Claim 2 narrows the corticosteroid option to methylprednisolone or dexamethasone. Claim 3 identifies ondansetron, granisetron, and metoclopramide as the relevant 5HT3-pathway agents.

The claim structure creates two separate infringement routes:

NK1 antagonist plus corticosteroid; and
NK1 antagonist plus 5HT3 antagonist.

A product regimen using aprepitant and dexamethasone would fall within the stated combination category if the other claim elements were satisfied. A regimen using aprepitant and ondansetron would fall within the 5HT3 combination category.

What chemotherapy indications are covered?

Claims 5 through 8 focus on chemotherapy-induced emesis. Claim 6 lists a broad group of cytotoxic agents, including:

Cisplatin;
Cyclophosphamide;
Doxorubicin;
Dacarbazine;
Etoposide;
Methotrexate;
5-fluorouracil;
Vinblastine and vincristine; and
Other listed alkylating, antimetabolite, anthracycline, vinca, and platinum agents.

Claims 7 and 8 narrow the chemotherapy trigger to cisplatin and cyclophosphamide, respectively. Cisplatin is commercially important because it is strongly emetogenic and historically drove the clinical development of NK1 antagonists.

Claim 9 extends the method to emesis induced by morphine, ipecacuanha, or copper sulfate. That claim is narrower in its trigger but broader than the chemotherapy claims in the type of emetic stimulus covered.

What does claim 10 cover?

Claim 10 defines the NK1 antagonist through extensive Markush structural language. It identifies permissible substituents and ring systems for Ar, R, R1, R2, R3, R11, Y, and Z, followed by pharmaceutically acceptable salts.

The listed structures include compounds containing:

Phenyl, substituted phenyl, thienyl, furyl, pyridyl, indolyl, quinolinyl, and naphthyl groups;
Cycloalkyl, norbornyl, quinuclidine, piperidine, and related bicyclic systems;
Methoxy, halo, trifluoromethyl, alkyl, alkoxy, cyano, nitro, amino, carboxy, and amide substituents; and
Branched alkyl, alkenyl, and aryl-containing side chains.

The provided text appears to combine multiple structural alternatives into a single continuous claim. The actual issued patent should be read with the chemical structure drawings, claim dependency, prosecution amendments, and any certificate of correction. Chemical scope cannot be determined reliably from the text alone where formula images or Markush boundaries are missing.

From an infringement perspective, claim 10 is not an independent commercial-use claim. It supplies the structural definition of the NK1 antagonist used in the combination claims. A candidate product must satisfy both the relevant chemical definition and the applicable treatment or composition limitations.

Which named NK1 antagonists are specifically covered?

Claims 13, 17, and 18 identify four specific NK1 antagonist structures:

Cis-3-(2-methoxybenzyl)amino-2-phenylpiperidine.
Cis-3-[(2-methoxyphenyl)methylamino]-2-benzhydryl-quinuclidine.
Cis-3-[(2-methoxybenzyl)amino]-2-diphenylmethyl-1-azabicyclo[2.2.2]octane.
The specified exo,exo azabicyclo[2.2.1]heptane derivative containing a 5-fluoro-2-methoxyphenylmethyl substituent.

These claims are materially narrower than the broad Markush language. They may provide stronger structural clarity but cover fewer molecules.

Aprepitant is the key commercial NK1 antagonist associated with the Emend product. The claims supplied by the user do not expressly name aprepitant. Whether aprepitant falls within claim 10 depends on the precise structural formula and the applicable claim construction. Commercial freedom-to-operate analysis therefore requires a structure-to-claim comparison, not merely a review of the drug name.

How do claims 11 through 25 differ from claims 1 through 10?

Claims 11 through 25 add a composition and regimen layer.

Composition claims

Claim 11 requires a pharmaceutical composition containing:

A 5HT3 receptor antagonist;
An NK1 receptor antagonist; and
A pharmaceutically acceptable carrier.

Claim 12 narrows the 5HT3 component to ondansetron or granisetron. Claim 13 narrows the NK1 component to four specified structures.

A single package or dosage form containing both active ingredients is the most direct target of claims 11 and 12. A kit containing separate dosage units may raise a different claim-construction issue depending on whether the kit is a "composition" and whether both active agents are present in the same pharmaceutical composition.

Treatment-method claims

Claim 14 covers administering the combination composition to treat or prevent emesis. Claim 16 covers administering the two active agents in amounts that make the combination effective, even if the claim does not expressly require a single combined composition.

Claims 20 and 21 address ondansetron-resistant emesis. These claims are commercially relevant to patients inadequately controlled by 5HT3 antagonists alone.

Claim 25 expressly covers separate administration under a dosing regimen. This provision is important because an NK1 antagonist and ondansetron do not need to be physically co-formulated to create potential claim coverage. Separate administration may still satisfy the claim if the combined regimen is effective and the other limitations are met.

What are the main claim-construction and validity issues?

The patent’s principal legal vulnerabilities arise from breadth, structural definition, and combination-therapy obviousness.

Written description and enablement

Claim 10 covers a large number of chemical combinations across multiple ring systems and substituent classes. A challenger could argue that the specification does not adequately describe or enable the full genus, particularly if the asserted molecule is structurally remote from the exemplified compounds.

The risk is lower for claims 13, 17, and 18 because those claims identify specific molecules.

Obviousness

A combination of an NK1 antagonist with ondansetron or dexamethasone could be challenged as an obvious antiemetic regimen if the prior art disclosed:

NK1 antagonists for emesis;
5HT3 antagonists for chemotherapy-induced emesis;
Corticosteroids as antiemetic adjuncts; and
A reasonable expectation that the agents would provide additive or improved control.

The patentee’s strongest response would be evidence of unexpected synergy, improved control of delayed emesis, or efficacy against ondansetron-resistant emesis.

Indefiniteness

Terms such as "effective amount," "in combination," and "amounts that render the combination effective" are common method-claim language but can generate factual disputes. The dose claims provide more objective boundaries, although the broad range in claim 22, approximately 0.1 to 400 mg/kg/day for the NK1 antagonist, remains expansive.

Claim 10 transcription risk

The supplied version of claim 10 repeats variable designations and appears to merge different formula definitions. Any legal opinion based on this text alone would be unreliable. The issued claim, patent drawings, prosecution history, and any correction certificate control.

When did US Patent 7,214,692 lose exclusivity?

US Patent 7,214,692 issued on May 8, 2007. Its enforceable term ended no later than the applicable twenty-year term measured from the relevant nonprovisional filing chain, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.

The patent is expired as of 2025. It therefore does not presently prevent a generic or innovator from practicing the claimed NK1-plus-5HT3 antiemetic combination in the United States.

A historical patent-term determination should distinguish:

Exclusivity type	Relevance
Patent term	Controlled by the filing chain and USPTO term calculation
FDA five-year NCE exclusivity	Applied to the approved active ingredient, not this combination patent
FDA three-year clinical-investigation exclusivity	May apply to a qualifying supplemental approval
Pediatric exclusivity	Adds six months to qualifying listed exclusivities
Orphan exclusivity	Applies only to the relevant orphan indication

The patent’s expiration did not necessarily terminate every exclusivity associated with Emend or other NK1 products. It removed this patent as a current patent barrier.

What was the Orange Book status of US Patent 7,214,692?

The Orange Book is relevant if the patent was listed against an approved drug product such as Emend. Orange Book listing does not determine validity or infringement. It creates a regulatory notice and, for an ANDA applicant making a Paragraph IV certification, may trigger the Hatch-Waxman litigation and 30-month-stay framework under 21 U.S.C. § 355(j).

The key regulatory distinctions are:

A patent claiming the approved drug substance can affect an ANDA for the active ingredient.
A method-of-use patent can affect only the patented indication or method.
A formulation or composition patent can affect an ANDA product only if the generic product practices the listed formulation limitations.
An expired patent no longer supports a current 30-month stay, although historical Paragraph IV litigation may remain relevant to launch timing and settlement analysis.

For aprepitant, the principal regulatory competition has involved ANDA products for capsules and injectable fosaprepitant products rather than biosimilar applications. Aprepitant is a small molecule, so the relevant pathway is generally an ANDA under section 505(j), not a biosimilar application under section 351(k).

Which companies challenged the Emend and aprepitant patent estate?

The commercial challenge has centered on generic manufacturers seeking approval for aprepitant capsules and related presentations. Publicly relevant participants in the broader aprepitant generic market have included Teva, Dr. Reddy's Laboratories, Glenmark, Mylan or Viatris, and other ANDA sponsors, depending on product, dosage form, and time period.

The specific company, patent, and Paragraph IV pairing must be assessed by ANDA litigation docket and FDA records. A generic company may challenge one patent while accepting others, use a section viii carve-out for a method-of-use patent, or launch after a settlement date without invalidating the patent.

Because US Patent 7,214,692 is expired, current generic entry risk does not depend on a live Paragraph IV challenge to this patent. The relevant risks instead arise from later patents covering:

Aprepitant formulations;
Micronized or particle-engineered drug substance;
Injectable fosaprepitant;
Prodrug technology;
Manufacturing processes;
Specific dosage regimens; and
Combination products with other antiemetics.

What patent landscape surrounds NK1 antiemetic combinations?

The patent estate divides into five technical layers.

NK1 chemical patents

These cover the molecular structure of aprepitant, netupitant, rolapitant, casopitant, and earlier development compounds. Chemical patents usually provide the strongest exclusion for the active ingredient but expire independently from combination patents.

Combination-treatment patents

US 7,214,692 is in this category. These patents cover NK1 antagonists administered with 5HT3 antagonists, corticosteroids, or other antiemetics.

Formulation patents

Formulation claims may cover:

Oral capsules;
Amorphous or crystalline forms;
Particle-size distributions;
Solid dispersions;
Injectable formulations;
Stability-enhancing excipients; and
Fixed-dose or co-packaged regimens.

Formulation patents can remain commercially important after a compound patent expires, particularly where the generic must use a specific solid-state form or manufacturing process.

Method-of-use patents

These claims may be directed to:

Highly emetogenic chemotherapy;
Moderately emetogenic chemotherapy;
Delayed chemotherapy-induced nausea and vomiting;
Rescue therapy;
Ondansetron-resistant emesis;
Postoperative nausea and vomiting; and
Specific dosing sequences involving dexamethasone or a 5HT3 antagonist.

A generic sponsor can sometimes omit a patented indication through a section viii labeling carve-out. That strategy is unavailable if the patented method is inseparable from the approved use or product label.

Manufacturing and process patents

Process patents may cover synthesis, crystallization, purification, salt formation, impurity control, and scale-up. They usually create a manufacturing risk rather than a direct product-labeling barrier. Their practical importance depends on whether the generic can use a non-infringing process and whether process discovery is available through litigation.

How does this patent compare with competing NK1 drugs?

Product	Active ingredient	Main combination role	Regulatory pathway	Biosimilar risk
Emend	Aprepitant	NK1 antagonist with 5HT3 antagonist and dexamethasone	NDA, followed by ANDA competition	None
IV Emend	Fosaprepitant	Injectable NK1 prodrug in chemotherapy regimens	NDA, followed by generic competition	None
Akynzeo	Netupitant plus palonosetron	Fixed NK1/5HT3 combination	NDA	None
Varubi	Rolapitant	NK1 antagonist, generally used with other antiemetics	NDA	None
Zyprexa-based regimens	Olanzapine	Adjunct antiemetic, not NK1 therapy	NDA/ANDA depending product	None

Akynzeo is the closest commercial comparator because it combines an NK1 antagonist and a 5HT3 antagonist in a single product. US 7,214,692 is conceptually relevant to that combination, but its expiration and the specific active-ingredient limitations mean that later netupitant, palonosetron, and formulation patents must be analyzed separately.

What generic launch scenarios existed?

Historically, four launch scenarios were possible:

Launch after patent expiry.
Paragraph IV launch after a successful invalidity or non-infringement challenge.
Authorized or settlement-based launch before patent expiry.
Section viii launch with patented indications removed from labeling.

For a product containing aprepitant and ondansetron, the expired status of US 7,214,692 eliminates this patent as a current launch obstacle. A generic sponsor still must assess active-ingredient, polymorph, formulation, process, and labeling patents.

For a fixed-dose NK1/5HT3 product, the risk profile is different. A single product may practice separate patents covering the NK1 molecule, 5HT3 molecule, co-formulation, dosing schedule, and manufacturing process.

How strong is the patent estate?

The patent was historically strong as a combination-use patent because it addressed the clinical standard of combining an NK1 antagonist with a 5HT3 antagonist and corticosteroid. Its commercial strength was reduced by several factors:

The patent did not claim every NK1 antagonist as a chemical entity.
Claim 10 used complex Markush language.
Combination therapy was technically predictable from the antiemetic prior art.
Generic sponsors could challenge method claims through Paragraph IV or use labeling strategies.
The patent has expired.

The narrower named-compound and composition claims were easier to analyze structurally, but they covered fewer products. The broadest commercial protection for aprepitant historically came from the separate compound and product patent estate, not from this combination patent alone.

What licensing and settlement issues affected the patent?

The principal commercial issue was not a broad license to the antiemetic field. It was the timing and scope of generic entry into the aprepitant market. Settlement agreements in Hatch-Waxman litigation may include:

A defined generic launch date;
A license limited to specified dosage forms;
Restrictions on authorized generic competition;
A covenant concerning particular indications;
A release limited to listed patents; or
No admission of validity or infringement.

A settlement involving an aprepitant patent does not automatically resolve exposure under US 7,214,692 unless that patent is expressly included. The same distinction applies to a settlement covering capsules but not injectable fosaprepitant.

What is the current competitive and revenue exposure?

Emend was a major antiemetic product during the period when NK1 therapy became standard for highly emetogenic chemotherapy. Current revenue exposure to US 7,214,692 is zero as an enforceable patent right because the patent has expired.

Commercial exposure now shifts to:

Generic price erosion for aprepitant;
Product differentiation by Akynzeo and other fixed-dose combinations;
IV versus oral administration;
Prevention of delayed nausea and vomiting;
Combination use with dexamethasone and 5HT3 antagonists;
Hospital formulary positioning; and
Manufacturing cost and supply reliability.

The combination concept remains clinically relevant, but the patent no longer provides exclusivity for that concept in the United States.

Key Takeaways

US 7,214,692 covers NK1 antagonist combinations with 5HT3 antagonists or systemic corticosteroids for emesis.
The most important commercial embodiments involve ondansetron, granisetron, dexamethasone, chemotherapy-induced emesis, and cisplatin.
Claims 11-25 extend protection to co-formulations, treatment methods, separate dosing regimens, specified compounds, dose ranges, and ondansetron-resistant emesis.
Claim 10 is a broad and technically complex Markush claim; the issued structural formula and prosecution history are required for precise molecule-by-molecule mapping.
Aprepitant is the central commercial product associated with this patent landscape, although the supplied claims do not expressly name it.
The patent is expired as of 2025 and is not a current US barrier to generic practice of the claimed combination.
Current competitive risk lies in later compound, formulation, process, injectable, and method-of-use patents.
Aprepitant is a small molecule. Biosimilar litigation under section 351(k) is not applicable.
Historical Paragraph IV litigation and settlements may explain generic launch timing, but they do not restore exclusivity after expiration.

FAQs

Does US Patent 7,214,692 cover aprepitant by name?

No. The supplied claims do not name aprepitant. Coverage depends on whether aprepitant falls within the structural alternatives in claim 10 and whether the relevant combination and treatment limitations are satisfied.

Does the patent cover aprepitant used with dexamethasone?

Potentially, under claim 1 and claim 2, if the NK1 antagonist satisfies the claim 10 structural limitations and the treatment is for a mammal suffering from or susceptible to emesis. The patent is expired.

Does ondansetron alone infringe this patent?

No. The claims require an NK1 antagonist in combination with ondansetron, granisetron, metoclopramide, or another claimed therapeutic agent. Ondansetron monotherapy does not satisfy the combination limitation.

Does separate administration of the two antiemetics fall within the claims?

Yes, claim 25 expressly addresses separate administration according to a dosing regimen that makes the combination effective. Claims 11 and 14 raise different issues because they focus more directly on a pharmaceutical composition.

Are biosimilars relevant to the Emend patent estate?

No. Aprepitant and fosaprepitant are small-molecule drugs. The relevant competitors use ANDA, 505(b)(2), or conventional NDA pathways rather than the biosimilar pathway.

References

United States Patent and Trademark Office. (2007). U.S. Patent No. 7,214,692, Combination therapy for the treatment of emesis.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs.
U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585.
U.S. Code, 21 U.S.C. § 355(j).
U.S. Code, 35 U.S.C. §§ 154, 156.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9120172.3	Sep 20, 1991
United Kingdom	9202839.8	Feb 11, 1992
United Kingdom	9204151.5	Feb 27, 1992

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	195867	⤷ Start Trial
Australia	2458392	⤷ Start Trial
Australia	657996	⤷ Start Trial
Canada	2078578	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 7,214,692